Vax-Innate | Cancer Vaccine Reduces Tumour Growth In Experiment

Vax-Innate | Cancer Vaccine reduces Tumour Growth In Experiment

Vax-Innate | Cancer Vaccine Reduces Tumour Growth – The vaccine weakens the cancer cells and prevents the suppression of T cells.


An experimental cancer vaccine proved extremely effective when tested on laboratory mice, according to a research team from the National Institutes of Health.

The new drug, developed by Dr. Robert Seder and colleagues at the NIAID Vaccine Research Center, successfully led to a dramatic regression of tumors in mice, raising hopes that experts may be closer to find an effective cancer treatment.

View More: Better Food Cold Chain Crucial For Climate, World Hunger: UN

The vaccine, called SNAPvax, was tested by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) in two different ways.

They used intravenous administration for administration and the results showed that this method increased cytotoxic T cells in mice.

Cytotoxic T cells are responsible for attacking cancerous tumor cells and activating the body’s immune system by activating type I interferons, which are proteins released by cells in response to viruses.

The study authors say that the natural immune response, accompanied by the introduction of the vaccine, alters the “microenvironment” of the tumor, which weakens the cancer cells and prevents the suppression of T-cell action.

They also try to administer drugs by injecting them under the skin. The subcutaneous method did not give the same results, and the intravenous method was considered the most effective form of delivery.

The medical breakthrough, published in the journal Cell, has been dubbed the “innate of the vaccine,” and scientists believe it could be a milestone in immunotherapy and cancer vaccine research.

The study authors hope the vaccine could also help patients who receive tumor-specific T cells during treatment.

Vaccines can often make the immune system healthier by controlling tumor growth and increasing the production of T cells.

Vaccitech, a Baltimore-based clinical-stage biopharmaceutical company, plans to test SNAPvax against human papillomavirus-associated cancer in 2023.

Click Here To Get More Information About Other News

Scroll to Top